175 related articles for article (PubMed ID: 30934098)
1. A Cautious Note on Thalidomide Usage in Cancer Treatment: Genetic Profiling of the TBX2 Sub-Family Gene Expression is Required.
Nemer G; Khalil A
Drug Res (Stuttg); 2019 Sep; 69(9):512-518. PubMed ID: 30934098
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide-a notorious sedative to a wonder anticancer drug.
Zhou S; Wang F; Hsieh TC; Wu JM; Wu E
Curr Med Chem; 2013; 20(33):4102-8. PubMed ID: 23931282
[TBL] [Abstract][Full Text] [Related]
3. Dermatologic therapeutics: thalidomide. A practical guide.
Rosenbach M; Werth VP
Dermatol Ther; 2007; 20(4):175-86. PubMed ID: 17970884
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide: an old sedative-hypnotic with anticancer activity?
Gasparini G; Morabito A; Magnani E; Gattuso D; Capaccetti B; Alberti AM
Curr Opin Investig Drugs; 2001 Sep; 2(9):1302-8. PubMed ID: 11717819
[TBL] [Abstract][Full Text] [Related]
5. Thalidomid: current role in the treatment of non-plasma cell malignancies.
Kumar S; Witzig TE; Rajkumar SV
J Clin Oncol; 2004 Jun; 22(12):2477-88. PubMed ID: 15197211
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of action and potential therapeutic uses of thalidomide.
Mujagić H; Chabner BA; Mujagić Z
Croat Med J; 2002 Jun; 43(3):274-85. PubMed ID: 12035132
[TBL] [Abstract][Full Text] [Related]
7. The molecular mechanism of thalidomide analogs in hematologic malignancies.
Lindner S; Krönke J
J Mol Med (Berl); 2016 Dec; 94(12):1327-1334. PubMed ID: 27492707
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Suppression of the T-box Subfamily 2 (
Nehme E; Rahal Z; Sinjab A; Khalil A; Chami H; Nemer G; Kadara H
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866410
[TBL] [Abstract][Full Text] [Related]
9. Importance of the interaction between immune cells and tumor vasculature mediated by thalidomide in cancer treatment (Review).
Wang X; Shen Y; Li S; Lv M; Zhang X; Yang J; Wang F; Yang J
Int J Mol Med; 2016 Oct; 38(4):1021-9. PubMed ID: 27599781
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide and analogues: current proposed mechanisms and therapeutic usage.
Brennen WN; Cooper CR; Capitosti S; Brown ML; Sikes RA
Clin Prostate Cancer; 2004 Jun; 3(1):54-61. PubMed ID: 15279692
[TBL] [Abstract][Full Text] [Related]
11. [Thalidomide--new prospective therapy in oncology].
Pałgan K; Pałgan I
Wiad Lek; 2003; 56(9-10):455-9. PubMed ID: 15049211
[TBL] [Abstract][Full Text] [Related]
12. Current status of thalidomide in the treatment of cancer.
Rajkumar SV
Oncology (Williston Park); 2001 Jul; 15(7):867-74; discussion 877-9. PubMed ID: 11499688
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide: an old drug with new action.
Kumar V; Chhibber S
J Chemother; 2011 Dec; 23(6):326-34. PubMed ID: 22233815
[TBL] [Abstract][Full Text] [Related]
14. Expression of T-box transcription factors 2, 4 and 5 is decreased in the branching airway mesenchyme of nitrofen-induced hypoplastic lungs.
Takahashi T; Friedmacher F; Zimmer J; Puri P
Pediatr Surg Int; 2017 Feb; 33(2):139-143. PubMed ID: 27833996
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications.
Bodera P; Stankiewicz W
Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):192-6. PubMed ID: 21913886
[TBL] [Abstract][Full Text] [Related]
16. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
[TBL] [Abstract][Full Text] [Related]
17. [Thalidomide teratogenicity and its direct target identification].
Ito T; Ando H; Handa H
Nihon Rinsho; 2015 Jan; 73(1):143-8. PubMed ID: 25626320
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide in the treatment of cancer.
Adlard JW
Anticancer Drugs; 2000 Nov; 11(10):787-91. PubMed ID: 11142686
[TBL] [Abstract][Full Text] [Related]
19. The promise of thalidomide: evolving indications.
Joglekar S; Levin M
Drugs Today (Barc); 2004 Mar; 40(3):197-204. PubMed ID: 15148528
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide: mechanisms of action.
Paravar T; Lee DJ
Int Rev Immunol; 2008; 27(3):111-35. PubMed ID: 18437602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
